long intergenic non-protein coding RNA 1626Genealiases: []
Q-omics provides the consensus-scored LINC01626 profile across patient tissues and cancer cell-line models. LINC01626 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC01626 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, LINC01626 RNA expression shows 6,289 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, KICH, and STAD as cancer lineages where LINC01626 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01626 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01626 survival associations across molecular data types. LINC01626 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01626 RNA expression–survival associations across cancer types. High LINC01626 expression shows unfavorable associations in COAD, BLCA, HNSC, ACC, ESCA and PAAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC01626 RNA expression.
This table summarizes LINC01626 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01626. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01626 shows lower tumor expression in BRCA and LUAD and higher tumor expression in KICH and THCA. The KICH box plot shows higher LINC01626 RNA expression in tumor versus normal tissue (log2 FC = +0.112, t-test p = .003).
This table shows molecular features associated with LINC01626 in patient tissues and cancer cell lines. In patient samples, LINC01626 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
